Lkh-Univ. Klinikum Graz

The trials here

What the 13 trials at this site are about, from their registry records.

Conditions

• Macular degeneration2 trials
• Psoriasis2 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• Crohn's disease1 trial
• Diabetic eye disease1 trial
• Familial hypercholesterolaemia1 trial
• Heart failure1 trial
• High blood pressure1 trial
• Hypertrophic cardiomyopathy1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• and 4 more

Phase

• Phase 36 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Completed4 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Hoffmann-La Roche6 trials
• Actelion1 trial
• Bristol-Myers Squibb1 trial
• Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 trial
• Janssen Pharmaceutica N.V., Belgium1 trial
• and 3 more

Running trials

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Hoffmann-La Roche· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

  NCT06680817· Hoffmann-La Roche· Source

• Recruiting

  A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  NCT05489705· Bristol-Myers Squibb· Source

  Contact: Nicolas Verheyen, Site 0087

• Active, not recruiting

  A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice

  NCT05049798· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT04579367· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Active, not recruiting

  Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia

  NCT04232241· Phase 2· Universitätsklinikum Hamburg-Eppendorf· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease1 recruiting
• Heart failure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Metastatic breast cancer1 recruiting

Closed trials

• Terminated

  A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

  NCT07449234· Janssen-Cilag Ltd.· Source

• Completed

  A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema

  NCT05642312· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration

  NCT04777201· Phase 3· Hoffmann-La Roche· Source

• Completed

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· Phase 3· Hoffmann-La Roche· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Actelion· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Hoffmann-La Roche· Source